Arrowhead Pharmaceuticals Management
Management criteria checks 3/4
Arrowhead Pharmaceuticals' CEO is Chris Anzalone, appointed in Dec 2007, has a tenure of 16.33 years. total yearly compensation is $9.92M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 3% of the company’s shares, worth $88.86M. The average tenure of the management team and the board of directors is 5.8 years and 13.4 years respectively.
Key information
Chris Anzalone
Chief executive officer
US$9.9m
Total compensation
| CEO salary percentage | 9.1% |
| CEO tenure | 16.3yrs |
| CEO ownership | 3.0% |
| Management average tenure | 5.8yrs |
| Board average tenure | 13.4yrs |
Recent management updates
Recent updates
Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03
Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices
Apr 14Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?
Feb 08Arrowhead: 2021 Was A Struggle Valuation Wise - Things May Get Worse In 2022
Jan 26Accumulate Arrowhead For Its RNAi Pipeline
Jan 17Johnson & Johnson's JNJ-3989 News Could Propel Arrowhead Stock To New All-Time Highs
Nov 03Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 34%?
Oct 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$297m |
| Sep 30 2023 | US$10m | US$903k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$181m |
| Mar 31 2023 | n/a | n/a | -US$150m |
| Dec 31 2022 | n/a | n/a | -US$155m |
| Sep 30 2022 | US$12m | US$863k | -US$176m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$183m |
| Sep 30 2021 | US$25m | US$837k | -US$141m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | n/a | n/a | -US$103m |
| Sep 30 2020 | US$14m | US$786k | -US$85m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | US$10m |
| Dec 31 2019 | n/a | n/a | US$53m |
| Sep 30 2019 | US$2m | US$674k | US$68m |
| Jun 30 2019 | n/a | n/a | US$46m |
| Mar 31 2019 | n/a | n/a | US$10m |
| Dec 31 2018 | n/a | n/a | -US$29m |
| Sep 30 2018 | US$2m | US$643k | -US$54m |
| Jun 30 2018 | n/a | n/a | -US$54m |
| Mar 31 2018 | n/a | n/a | -US$44m |
| Dec 31 2017 | n/a | n/a | -US$35m |
| Sep 30 2017 | US$2m | US$616k | -US$34m |
Compensation vs Market: Chris's total compensation ($USD9.92M) is above average for companies of similar size in the US market ($USD6.66M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Anzalone (54 yo)
16.3yrs
Tenure
US$9,918,093
Compensation
Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 16.3yrs | US$9.92m | 3% $ 88.9m | |
| Chief Financial Officer | 14.2yrs | US$3.12m | 0.19% $ 5.6m | |
| COO, General Counsel & Secretary | 9.3yrs | US$3.31m | 0.23% $ 6.8m | |
| Chief of Discovery & Translational Medicine | no data | US$3.05m | 0.17% $ 4.9m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | no data | no data | |
| Head of Investor Relations & VP | no data | no data | no data | |
| Director of Communications | 18.7yrs | no data | no data | |
| Chief Medical Scientist | less than a year | US$16.34m | no data | |
| Head of Toxicology & VP | no data | no data | no data | |
| Chief Commercial Officer | 1.8yrs | US$2.97m | 0.0073% $ 215.2k | |
| Head of Tax | 2.3yrs | no data | no data | |
| VP & Treasurer | 2.3yrs | no data | no data |
5.8yrs
Average Tenure
59yo
Average Age
Experienced Management: ARWR's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 16.3yrs | US$9.92m | 3% $ 88.9m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | no data | no data | |
| Chairman of the Board | 13.4yrs | US$474.60k | 0.11% $ 3.4m | |
| Independent Lead Director | 12.3yrs | US$459.60k | 0.074% $ 2.2m | |
| Independent Director | 6.3yrs | US$469.60k | 0.027% $ 786.5k | |
| Member of Hepatitis B Clinical Advisory Board | no data | no data | no data | |
| Chairman of Hepatitis B Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 13.7yrs | US$459.60k | 0.037% $ 1.1m | |
| Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board | no data | no data | no data | |
| Member of Hepatitis B Clinical Advisory Board | no data | no data | no data | |
| Member of Hepatitis B Clinical Advisory Board | no data | no data | no data | |
| Member of Hepatitis B Clinical Advisory Board | no data | no data | no data |
13.4yrs
Average Tenure
64yo
Average Age
Experienced Board: ARWR's board of directors are seasoned and experienced ( 13.4 years average tenure).